Jim Polson is a Senior Managing Director in the Strategic Communications Segment of FTI Consulting (NYSE:FCN), providing financial communications counsel to a broad range of clients across the market cap spectrum.
Jim leads FTI's Healthcare & Life Sciences Financial Communications practice, having worked with a diverse set of clients such as Alexion Pharmaceuticals, BioXcel Therapeutics, Adaptimmune, Surgery Partners, bluebird Bio, Enhabit, Humana, Catalent, and Takeda, among many others.
As a result of implementing and managing best practice investor relations programs for his clients, Jim has significant experience advising companies on critical shareholder communication issues including strategic message development, corporate governance, investor targeting and engagement, valuation analysis, and in-depth perception research audits.
In addition, Jim has extensive experience leading Board level projects around event driven catalysts such as mergers and acquisitions, initial public offerings or capital raises, shareholder activism, management transitions, and other crisis communications issues that can impact valuation.
Jim joined FTI Consulting as part of the acquisition of Ashton Partners in October 2007. Prior to joining Ashton Partners, Jim's experience entailed a strong background in the markets and financial analysis. He most recently worked at the Chicago Board of Trade in market regulation, and prior to that worked at Friedman Billings and Ramsey in equity research. Jim graduated from Michigan State University with dual degrees in Economics and Political Science, and also received a M.B.A. with a concentration in Finance from DePaul University.